Publications Molecular Biology of Sarcomas

Publications from OUS - Molecular characterization of mesenchymal cancer development

92 publications found

Publications 2020

  1. Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
    Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
    Cancer Biol Ther, 21 (5), 432-440
    DOI 10.1080/15384047.2020.1721252, PubMed 32098573
  2. Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
    Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
    Transl Oncol, 13 (8), 100793
    DOI 10.1016/j.tranon.2020.100793, PubMed 32447231
  3. Georgiesh T, Boye K, Bjerkehagen B (2020)
    A novel risk score to predict early and late recurrence in solitary fibrous tumour
    Histopathology, 77 (1), 123-132
    DOI 10.1111/his.14078, PubMed 31991494
  4. Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
    Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
    Acta Oncol, 59 (7), 733-740
    DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
  5. Serguienko A, Braadland P, Meza-Zepeda LA, Bjerkehagen B, Myklebost O (2020)
    Accurate 3-gene-signature for early diagnosis of liposarcoma progression
    Clin Sarcoma Res, 10, 4
    DOI 10.1186/s13569-020-0126-1, PubMed 32158531
  6. Wise JF, Nakken S, Steen CB, Vodák D, Trøen G, Johannessen B, Lingjærde OC, Hilden V, Blaker YN, Bai B, Aasheim LB, Pasanen A, Lorenz S, Sveen A, Lothe RA, Myklebost O, Leppä S, Meza-Zepeda LA, Beiske K, Lawrence MS, Hovig E, Myklebust JH, Smeland EB, Holte H (2020)
    Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series
    Blood Adv, 4 (9), 1859-1866
    DOI 10.1182/bloodadvances.2019001325, PubMed 32374878

Publications 2019

  1. Forthun RB, Hovland R, Schuster C, Puntervoll H, Brodal HP, Namløs HM, Aasheim LB, Meza-Zepeda LA, Gjertsen BT, Knappskog S, Straume O (2019)
    ctDNA detected by ddPCR reveals changes in tumour load in metastatic malignant melanoma treated with bevacizumab
    Sci Rep, 9 (1), 17471
    DOI 10.1038/s41598-019-53917-5, PubMed 31767937
  2. Goodridge JP, Jacobs B, Saetersmoen ML, Clement D, Hammer Q, Clancy T, Skarpen E, Brech A, Landskron J, Grimm C, Pfefferle A, Meza-Zepeda L, Lorenz S, Wiiger MT, Louch WE, Ask EH, Liu LL, Oei VYS, Kjällquist U, Linnarsson S, Patel S, Taskén K, Stenmark H, Malmberg KJ (2019)
    Remodeling of secretory lysosomes during education tunes functional potential in NK cells
    Nat Commun, 10 (1), 514
    DOI 10.1038/s41467-019-08384-x, PubMed 30705279
  3. Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O (2019)
    Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma
    Cells, 8 (2)
    DOI 10.3390/cells8020189, PubMed 30795553
  4. Hausott B, Förste A, Zach F, Mangger S, Haugsten EM, Klimaschewski L (2019)
    Endocytosis and Transport of Growth Factor Receptors in Peripheral Axon Regeneration: Novel Lessons from Neurons Expressing Lysine-Deficient FGF Receptor Type 1 in vitro
    Anat Rec (Hoboken), 302 (8), 1268-1275
    DOI 10.1002/ar.24120, PubMed 30950230
  5. Namløs HM, Boye K, Meza-Zepeda LA (2019)
    Cell-free DNA in blood as a noninvasive insight into the sarcoma genome
    Mol Aspects Med, 72, 100827
    DOI 10.1016/j.mam.2019.10.004, PubMed 31703948
  6. Pashov A, Shivarov V, Hadzhieva M, Kostov V, Ferdinandov D, Heintz KM, Pashova S, Todorova M, Vassilev T, Kieber-Emmons T, Meza-Zepeda LA, Hovig E (2019)
    Diagnostic Profiling of the Human Public IgM Repertoire With Scalable Mimotope Libraries
    Front Immunol, 10, 2796
    DOI 10.3389/fimmu.2019.02796, PubMed 31849974
  7. Sneeggen M, Pedersen NM, Campsteijn C, Haugsten EM, Stenmark H, Schink KO (2019)
    WDFY2 restrains matrix metalloproteinase secretion and cell invasion by controlling VAMP3-dependent recycling
    Nat Commun, 10 (1), 2850
    DOI 10.1038/s41467-019-10794-w, PubMed 31253801
  8. Szybowska P, Kostas M, Wesche J, Wiedlocha A, Haugsten EM (2019)
    Cancer Mutations in FGFR2 Prevent a Negative Feedback Loop Mediated by the ERK1/2 Pathway
    Cells, 8 (6)
    DOI 10.3390/cells8060518, PubMed 31146385
  9. Zakrzewska M, Opalinski L, Haugsten EM, Otlewski J, Wiedlocha A (2019)
    Crosstalk between p38 and Erk 1/2 in Downregulation of FGF1-Induced Signaling
    Int J Mol Sci, 20 (8)
    DOI 10.3390/ijms20081826, PubMed 31013829

Publications 2018

  1. Birkeland E, Zhang S, Poduval D, Geisler J, Nakken S, Vodak D, Meza-Zepeda LA, Hovig E, Myklebost O, Knappskog S, Lønning PE (2018)
    Patterns of genomic evolution in advanced melanoma
    Nat Commun, 9 (1), 2665
    DOI 10.1038/s41467-018-05063-1, PubMed 29991680
  2. Fafilek B, Balek L, Bosakova MK, Varecha M, Nita A, Gregor T, Gudernova I, Krenova J, Ghosh S, Piskacek M, Jonatova L, Cernohorsky NH, Zieba JT, Kostas M, Haugsten EM, Wesche J, Erneux C, Trantirek L, Krakow D, Krejci P (2018)
    The inositol phosphatase SHIP2 enables sustained ERK activation downstream of FGF receptors by recruiting Src kinases
    Sci Signal, 11 (548)
    DOI 10.1126/scisignal.aap8608, PubMed 30228226
  3. Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E (2018)
    Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas
    Int J Mol Sci, 19 (4)
    DOI 10.3390/ijms19040969, PubMed 29570692
  4. Kostas M, Haugsten EM, Zhen Y, Sørensen V, Szybowska P, Fiorito E, Lorenz S, Jones N, de Souza GA, Wiedlocha A, Wesche J (2018)
    Protein Tyrosine Phosphatase Receptor Type G (PTPRG) Controls Fibroblast Growth Factor Receptor (FGFR) 1 Activity and Influences Sensitivity to FGFR Kinase Inhibitors
    Mol Cell Proteomics, 17 (5), 850-870
    DOI 10.1074/mcp.RA117.000538, PubMed 29371290
  5. Kresse SH, Namløs HM, Lorenz S, Berner JM, Myklebost O, Bjerkehagen B, Meza-Zepeda LA (2018)
    Evaluation of commercial DNA and RNA extraction methods for high-throughput sequencing of FFPE samples
    PLoS One, 13 (5), e0197456
    DOI 10.1371/journal.pone.0197456, PubMed 29771965
  6. Løvf M, Zhao S, Axcrona U, Johannessen B, Bakken AC, Carm KT, Hoff AM, Myklebost O, Meza-Zepeda LA, Lie AK, Axcrona K, Lothe RA, Skotheim RI (2018)
    Multifocal Primary Prostate Cancer Exhibits High Degree of Genomic Heterogeneity
    Eur Urol, 75 (3), 498-505
    DOI 10.1016/j.eururo.2018.08.009, PubMed 30181068
  7. Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA (2018)
    Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor
    Mol Cancer Ther, 17 (11), 2473-2480
    DOI 10.1158/1535-7163.MCT-18-0174, PubMed 30097488
  8. Vodák D, Lorenz S, Nakken S, Aasheim LB, Holte H, Bai B, Myklebost O, Meza-Zepeda LA, Hovig E (2018)
    Sample-Index Misassignment Impacts Tumour Exome Sequencing
    Sci Rep, 8 (1), 5307
    DOI 10.1038/s41598-018-23563-4, PubMed 29593270
  9. Zhen Y, Haugsten EM, Singh SK, Wesche J (2018)
    Proximity Labeling by a Recombinant APEX2-FGF1 Fusion Protein Reveals Interaction of FGF1 with the Proteoglycans CD44 and CSPG4
    Biochemistry, 57 (26), 3807-3816
    DOI 10.1021/acs.biochem.8b00120, PubMed 29812912

Publications 2017

  1. Behjati S, Tarpey PS, Haase K, Ye H, Young MD, Alexandrov LB, Farndon SJ, Collord G, Wedge DC, Martincorena I, Cooke SL, Davies H, Mifsud W, Lidgren M, Martin S, Latimer C, Maddison M, Butler AP, Teague JW, Pillay N, Shlien A, McDermott U, Futreal PA, Baumhoer D, Zaikova O et al. (2017)
    Recurrent mutation of IGF signalling genes and distinct patterns of genomic rearrangement in osteosarcoma
    Nat Commun, 8, 15936
    DOI 10.1038/ncomms15936, PubMed 28643781
  2. Berg KCG, Eide PW, Eilertsen IA, Johannessen B, Bruun J, Danielsen SA, Bjørnslett M, Meza-Zepeda LA, Eknæs M, Lind GE, Myklebost O, Skotheim RI, Sveen A, Lothe RA (2017)
    Multi-omics of 34 colorectal cancer cell lines - a resource for biomedical studies
    Mol Cancer, 16 (1), 116
    DOI 10.1186/s12943-017-0691-y, PubMed 28683746
  3. Egeland EV, Boye K, Park D, Synnestvedt M, Sauer T, Oslo Breast Cancer Consortium (OSBREAC), Naume B, Borgen E, Mælandsmo GM (2017)
    Prognostic significance of S100A4-expression and subcellular localization in early-stage breast cancer
    Breast Cancer Res Treat, 162 (1), 127-137
    DOI 10.1007/s10549-016-4096-1, PubMed 28058579
  4. Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E (2017)
    Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b
    Sci Rep, 7 (1), 9655
    DOI 10.1038/s41598-017-10189-1, PubMed 28848235
  5. Helland Å, Brustugun OT, Nakken S, Halvorsen AR, Dønnem T, Bremnes R, Busund LT, Sun J, Lorenz S, Solberg SK, Jørgensen LH, Vodak D, Myklebost O, Hovig E, Meza-Zepeda LA (2017)
    High number of kinome-mutations in non-small cell lung cancer is associated with reduced immune response and poor relapse-free survival
    Int J Cancer, 141 (1), 184-190
    DOI 10.1002/ijc.30726, PubMed 28387924
  6. Hompland I, Bruland ØS, Hølmebakk T, Poulsen JP, Stoldt S, Hall KS, Boye K (2017)
    Prediction of long-term survival in patients with metastatic gastrointestinal stromal tumor: analysis of a large, single-institution cohort
    Acta Oncol, 56 (10), 1317-1323
    DOI 10.1080/0284186X.2017.1330555, PubMed 28557540
  7. Namløs HM, Zaikova O, Bjerkehagen B, Vodák D, Hovig E, Myklebost O, Boye K, Meza-Zepeda LA (2017)
    Use of liquid biopsies to monitor disease progression in a sarcoma patient: a case report
    BMC Cancer, 17 (1), 29
    DOI 10.1186/s12885-016-2992-8, PubMed 28061772
  8. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
    Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
    ESMO Open, 2 (2), e000158
    DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
  9. Rustad EH, Coward E, Skytøen ER, Misund K, Holien T, Standal T, Børset M, Beisvag V, Myklebost O, Meza-Zepeda LA, Dai HY, Sundan A, Waage A (2017)
    Monitoring multiple myeloma by quantification of recurrent mutations in serum
    Haematologica, 102 (7), 1266-1272
    DOI 10.3324/haematol.2016.160564, PubMed 28385781
  10. Serguienko A, Hanes R, Grad I, Wang MY, Myklebost O, Munthe E (2017)
    PP2A Regulatory Subunit B55γ is a Gatekeeper of Osteoblast Maturation and Lineage Maintenance
    Stem Cells Dev, 26 (19), 1375-1383
    DOI 10.1089/scd.2017.0129, PubMed 28805158
  11. Sveen A, Johannessen B, Tengs T, Danielsen SA, Eilertsen IA, Lind GE, Berg KCG, Leithe E, Meza-Zepeda LA, Domingo E, Myklebost O, Kerr D, Tomlinson I, Nesbakken A, Skotheim RI, Lothe RA (2017)
    Multilevel genomics of colorectal cancers with microsatellite instability-clinical impact of JAK1 mutations and consensus molecular subtype 1
    Genome Med, 9 (1), 46
    DOI 10.1186/s13073-017-0434-0, PubMed 28539123

Publications 2016

  1. Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA et al. (2016)
    Monogenic and polygenic determinants of sarcoma risk: an international genetic study
    Lancet Oncol, 17 (9), 1261-71
    DOI 10.1016/S1470-2045(16)30147-4, PubMed 27498913
  2. Barøy T, Chilamakuri CS, Lorenz S, Sun J, Bruland ØS, Myklebost O, Meza-Zepeda LA (2016)
    Genome Analysis of Osteosarcoma Progression Samples Identifies FGFR1 Overexpression as a Potential Treatment Target and CHM as a Candidate Tumor Suppressor Gene
    PLoS One, 11 (9), e0163859
    DOI 10.1371/journal.pone.0163859, PubMed 27685995
  3. Halvorsen AR, Silwal-Pandit L, Meza-Zepeda LA, Vodak D, Vu P, Sagerup C, Hovig E, Myklebost O, Børresen-Dale AL, Brustugun OT, Helland Å (2016)
    TP53 Mutation Spectrum in Smokers and Never Smoking Lung Cancer Patients
    Front Genet, 7, 85
    DOI 10.3389/fgene.2016.00085, PubMed 27242894
  4. Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O (2016)
    Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma
    Oncotarget, 7 (34), 54583-54595
    DOI 10.18632/oncotarget.10518, PubMed 27409346
  5. Lorenz S, Barøy T, Sun J, Nome T, Vodák D, Bryne JC, Håkelien AM, Fernandez-Cuesta L, Möhlendick B, Rieder H, Szuhai K, Zaikova O, Ahlquist TC, Thomassen GO, Skotheim RI, Lothe RA, Tarpey PS, Campbell P, Flanagan A, Myklebost O, Meza-Zepeda LA (2016)
    Unscrambling the genomic chaos of osteosarcoma reveals extensive transcript fusion, recurrent rearrangements and frequent novel TP53 aberrations
    Oncotarget, 7 (5), 5273-88
    DOI 10.18632/oncotarget.6567, PubMed 26672768
  6. Munthe E, Riss PJ, Saga TA, Haraldsen I, Grad I, Bogsrud TV, Bach-Gansmo T (2016)
    FDG-based quantitative comparison of glucose metabolism in vitro, exemplified by a head-to-head comparison between a triple-negative breast cancer cell line and a non-malignant foetal cell line
    Clin Physiol Funct Imaging, 38 (1), 34-37
    DOI 10.1111/cpf.12378, PubMed 27297457
  7. Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Schneider-Stock R, Ståhlberg A, Åman P (2016)
    HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo
    Oncotarget, 7 (1), 433-45
    DOI 10.18632/oncotarget.6336, PubMed 26595521
  8. Sandhu V, Wedge DC, Bowitz Lothe IM, Labori KJ, Dentro SC, Buanes T, Skrede ML, Dalsgaard AM, Munthe E, Myklebost O, Lingjærde OC, Børresen-Dale AL, Ikdahl T, Van Loo P, Nord S, Kure EH (2016)
    The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma
    Cancer Res, 76 (17), 5092-102
    DOI 10.1158/0008-5472.CAN-16-0658, PubMed 27488532
  9. Våtsveen TK, Børset M, Dikic A, Tian E, Micci F, Lid AH, Meza-Zepeda LA, Coward E, Waage A, Sundan A, Kuehl WM, Holien T (2016)
    VOLIN and KJON-Two novel hyperdiploid myeloma cell lines
    Genes Chromosomes Cancer, 55 (11), 890-901
    DOI 10.1002/gcc.22388, PubMed 27311012

Publications 2015

  1. Chymkowitch P, Nguéa AP, Aanes H, Koehler CJ, Thiede B, Lorenz S, Meza-Zepeda LA, Klungland A, Enserink JM (2015)
    Sumoylation of Rap1 mediates the recruitment of TFIID to promote transcription of ribosomal protein genes
    Genome Res, 25 (6), 897-906
    DOI 10.1101/gr.185793.114, PubMed 25800674
  2. Fernandez-Cuesta L, Sun R, Menon R, George J, Lorenz S, Meza-Zepeda LA, Peifer M, Plenker D, Heuckmann JM, Leenders F, Zander T, Dahmen I, Koker M, Schöttle J, Ullrich RT, Altmüller J, Becker C, Nürnberg P, Seidel H, Böhm D, Göke F, Ansén S, Russell PA, Wright GM, Wainer Z et al. (2015)
    Identification of novel fusion genes in lung cancer using breakpoint assembly of transcriptome sequencing data
    Genome Biol, 16, 7
    DOI 10.1186/s13059-014-0558-0, PubMed 25650807
  3. Kanojia D, Nagata Y, Garg M, Lee DH, Sato A, Yoshida K, Sato Y, Sanada M, Mayakonda A, Bartenhagen C, Klein HU, Doan NB, Said JW, Mohith S, Gunasekar S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Myklebost O, Yang H, Dugas M, Meza-Zepeda LA, Silberman AW, Forscher C et al. (2015)
    Genomic landscape of liposarcoma
    Oncotarget, 6 (40), 42429-44
    DOI 10.18632/oncotarget.6464, PubMed 26643872
  4. Myklebost O (2015)
    Personalized cancer therapy for soft tissue sarcomas: progress and pitfalls
    Per Med, 12 (6), 593-602
    DOI 10.2217/pme.15.20, PubMed 29750616
  5. Naderi EH, Skah S, Ugland H, Myklebost O, Sandnes DL, Torgersen ML, Josefsen D, Ruud E, Naderi S, Blomhoff HK (2015)
    Bone marrow stroma-derived PGE2 protects BCP-ALL cells from DNA damage-induced p53 accumulation and cell death
    Mol Cancer, 14, 14
    DOI 10.1186/s12943-014-0278-9, PubMed 25623255
  6. Rustad EH, Dai HY, Hov H, Coward E, Beisvag V, Myklebost O, Hovig E, Nakken S, Vodák D, Meza-Zepeda LA, Sandvik AK, Wader KF, Misund K, Sundan A, Aarset H, Waage A (2015)
    BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosis
    Blood Cancer J, 5, e299
    DOI 10.1038/bcj.2015.24, PubMed 25794135
  7. Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E (2015)
    Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA
    Oncotarget, 6 (4), 2451-65
    DOI 10.18632/oncotarget.3235, PubMed 25669981

Publications 2014

  1. Barøy T, Kresse SH, Skårn M, Stabell M, Castro R, Lauvrak S, Llombart-Bosch A, Myklebost O, Meza-Zepeda LA (2014)
    Reexpression of LSAMP inhibits tumor growth in a preclinical osteosarcoma model
    Mol Cancer, 13, 93
    DOI 10.1186/1476-4598-13-93, PubMed 24885297
  2. Garsed DW, Marshall OJ, Corbin VD, Hsu A, Di Stefano L, Schröder J, Li J, Feng ZP, Kim BW, Kowarsky M, Lansdell B, Brookwell R, Myklebost O, Meza-Zepeda L, Holloway AJ, Pedeutour F, Choo KH, Damore MA, Deans AJ, Papenfuss AT, Thomas DM (2014)
    The architecture and evolution of cancer neochromosomes
    Cancer Cell, 26 (5), 653-67
    DOI 10.1016/j.ccell.2014.09.010, PubMed 25517748
  3. Tubio JMC, Li Y, Ju YS, Martincorena I, Cooke SL, Tojo M, Gundem G, Pipinikas CP, Zamora J, Raine K, Menzies A, Roman-Garcia P, Fullam A, Gerstung M, Shlien A, Tarpey PS, Papaemmanuil E, Knappskog S, Van Loo P, Ramakrishna M, Davies HR, Marshall J, Wedge DC, Teague JW, Butler AP et al. (2014)
    Mobile DNA in cancer. Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes
    Science, 345 (6196), 1251343
    DOI 10.1126/science.1251343, PubMed 25082706
  4. Wennerström AB, Lothe IM, Sandhu V, Kure EH, Myklebost O, Munthe E (2014)
    Generation and characterisation of novel pancreatic adenocarcinoma xenograft models and corresponding primary cell lines
    PLoS One, 9 (8), e103873
    DOI 10.1371/journal.pone.0103873, PubMed 25148029

Publications 2013

  1. Behjati S, Tarpey PS, Presneau N, Scheipl S, Pillay N, Van Loo P, Wedge DC, Cooke SL, Gundem G, Davies H, Nik-Zainal S, Martin S, McLaren S, Goodie V, Robinson B, Butler A, Teague JW, Halai D, Khatri B, Myklebost O, Baumhoer D, Jundt G, Hamoudi R, Tirabosco R, Amary MF et al. (2013)
    Distinct H3F3A and H3F3B driver mutations define chondroblastoma and giant cell tumor of bone
    Nat Genet, 45 (12), 1479-82
    DOI 10.1038/ng.2814, PubMed 24162739
  2. Haugsten EM, Oppelt A, Wesche J (2013)
    Phosphatidylinositol 5-phosphate is a second messenger important for cell migration
    Commun Integr Biol, 6 (5), e25446
    DOI 10.4161/cib.25446, PubMed 24265857

Publications 2012

  1. Kresse SH, Rydbeck H, Skårn M, Namløs HM, Barragan-Polania AH, Cleton-Jansen AM, Serra M, Liestøl K, Hogendoorn PC, Hovig E, Myklebost O, Meza-Zepeda LA (2012)
    Integrative analysis reveals relationships of genetic and epigenetic alterations in osteosarcoma
    PLoS One, 7 (11), e48262
    DOI 10.1371/journal.pone.0048262, PubMed 23144859
  2. Namløs HM, Kresse SH, Müller CR, Henriksen J, Holdhus R, Sæter G, Bruland OS, Bjerkehagen B, Steen VM, Myklebost O (2012)
    Global gene expression profiling of human osteosarcomas reveals metastasis-associated chemokine pattern
    Sarcoma, 2012, 639038
    DOI 10.1155/2012/639038, PubMed 22518090
  3. Namløs HM, Meza-Zepeda LA, Barøy T, Østensen IH, Kresse SH, Kuijjer ML, Serra M, Bürger H, Cleton-Jansen AM, Myklebost O (2012)
    Modulation of the osteosarcoma expression phenotype by microRNAs
    PLoS One, 7 (10), e48086
    DOI 10.1371/journal.pone.0048086, PubMed 23133552

Publications 2011

  1. Kresse SH, Meza-Zepeda LA, Machado I, Llombart-Bosch A, Myklebost O (2011)
    Preclinical xenograft models of human sarcoma show nonrandom loss of aberrations
    Cancer, 118 (2), 558-70
    DOI 10.1002/cncr.26276, PubMed 21713766
  2. Stratford EW, Castro R, Wennerstrom A, Holm R, Munthe E, Lauvrak S, Bjerkehagen B, Myklebost O (2011)
    Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential
    Clin Sarcoma Res, 1 (1), 8
    DOI 10.1186/2045-3329-1-8, PubMed 22612877
  3. Thomas DM, Wilhelm M, Cleton-Jansen AM, Dirksen U, Entz-Werlé N, Gelderblom H, Hassan B, Jürgens H, Koster J, Kovar H, Lankester AC, Lewis IJ, Myklebost O, Nathrath MH, Picci P, Whelan JS, Hogendoorn PC, Bielack SS (2011)
    Workshop Report on the European Bone Sarcoma Networking Meeting: Integration of Clinical Trials with Tumor Biology
    J Adolesc Young Adult Oncol, 1 (3), 118-23
    DOI 10.1089/jayao.2012.0005, PubMed 26811922

Publications 2010

  1. Eide MB, Liestøl K, Lingjaerde OC, Hystad ME, Kresse SH, Meza-Zepeda L, Myklebost O, Trøen G, Aamot HV, Holte H, Smeland EB, Delabie J (2010)
    Genomic alterations reveal potential for higher grade transformation in follicular lymphoma and confirm parallel evolution of tumor cell clones
    Blood, 116 (9), 1489-97
    DOI 10.1182/blood-2010-03-272278, PubMed 20505157
  2. Kresse SH, Ohnstad HO, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2010)
    DNA copy number changes in human malignant fibrous histiocytomas by array comparative genomic hybridisation
    PLoS One, 5 (11), e15378
    DOI 10.1371/journal.pone.0015378, PubMed 21085701
  3. Kresse SH, Szuhai K, Barragan-Polania AH, Rydbeck H, Cleton-Jansen AM, Myklebost O, Meza-Zepeda LA (2010)
    Evaluation of high-resolution microarray platforms for genomic profiling of bone tumours
    BMC Res Notes, 3, 223
    DOI 10.1186/1756-0500-3-223, PubMed 20691109
  4. Soler E, Andrieu-Soler C, de Boer E, Bryne JC, Thongjuea S, Stadhouders R, Palstra RJ, Stevens M, Kockx C, van IJcken W, Hou J, Steinhoff C, Rijkers E, Lenhard B, Grosveld F (2010)
    The genome-wide dynamics of the binding of Ldb1 complexes during erythroid differentiation (vol 24, pg 277, 2010)
    Genes Dev., 24 (6), 623

Publications 2009

  1. Kresse SH, Ohnstad HO, Paulsen EB, Bjerkehagen B, Szuhai K, Serra M, Schaefer KL, Myklebost O, Meza-Zepeda LA (2009)
    LSAMP, a novel candidate tumor suppressor gene in human osteosarcomas, identified by array comparative genomic hybridization
    Genes Chromosomes Cancer, 48 (8), 679-93
    DOI 10.1002/gcc.20675, PubMed 19441093
  2. Myklebost O, Noordhuis P (2009)
    Bone marrow stroma cells regulate TIEG1 expression in acute lymphoblastic leukemia cells: Role of TGF beta/BMP-6 and TIEG1 in chemotherapy escape. (vol 123, pg 2759, 2008)
    Int. J. Cancer, 124 (9), 2250

Publications 2008

  1. Kresse SH, Skårn M, Ohnstad HO, Namløs HM, Bjerkehagen B, Myklebost O, Meza-Zepeda LA (2008)
    DNA copy number changes in high-grade malignant peripheral nerve sheath tumors by array CGH
    Mol Cancer, 7, 48
    DOI 10.1186/1476-4598-7-48, PubMed 18522746
  2. Meza-Zepeda LA, Noer A, Dahl JA, Micci F, Myklebost O, Collas P (2008)
    High-resolution analysis of genetic stability of human adipose tissue stem cells cultured to senescence
    J Cell Mol Med, 12 (2), 553-63
    DOI 10.1111/j.1582-4934.2007.00146.x, PubMed 18419597

Publications 2007

  1. Müller CR, Paulsen EB, Noordhuis P, Pedeutour F, Saeter G, Myklebost O (2007)
    Potential for treatment of liposarcomas with the MDM2 antagonist Nutlin-3A
    Int J Cancer, 121 (1), 199-205
    DOI 10.1002/ijc.22643, PubMed 17354236

Publications 2006

  1. Berner JM, Muller CR, Holden M, Wang J, Hovig E, Myklebost O (2006)
    Sampling effects on gene expression data from a human tumour xenograft
    Scand. J. Lab. Anim. Sci., 33 (1), 17-30
  2. MAQC Consortium, Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, Luo Y, Sun YA, Willey JC, Setterquist RA, Fischer GM, Tong W, Dragan YP, Dix DJ, Frueh FW, Goodsaid FM, Herman D, Jensen RV, Johnson CD, Lobenhofer EK et al. (2006)
    The MicroArray Quality Control (MAQC) project shows inter- and intraplatform reproducibility of gene expression measurements
    Nat Biotechnol, 24 (9), 1151-61
    DOI 10.1038/nbt1239, PubMed 16964229
  3. Meza-Zepeda LA, Kresse SH, Barragan-Polania AH, Bjerkehagen B, Ohnstad HO, Namløs HM, Wang J, Kristiansen BE, Myklebost O (2006)
    Array comparative genomic hybridization reveals distinct DNA copy number differences between gastrointestinal stromal tumors and leiomyosarcomas
    Cancer Res, 66 (18), 8984-93
    DOI 10.1158/0008-5472.CAN-06-1972, PubMed 16982739
  4. Sivertsen EA, Galteland E, Mu D, Holte H, Meza-Zepeda L, Myklebost O, Patzke S, Smeland EB, Stokke T (2006)
    Gain of chromosome 6p is an infrequent cause of increased PIM1 expression in B-cell non-Hodgkin's lymphomas
    Leukemia, 20 (3), 539-42
    DOI 10.1038/sj.leu.2404094, PubMed 16437153

Publications 2005

  1. Kresse SH, Berner JM, Meza-Zepeda LA, Gregory SG, Kuo WL, Gray JW, Forus A, Myklebost O (2005)
    Mapping and characterization of the amplicon near APOA2 in 1q23 in human sarcomas by FISH and array CGH
    Mol Cancer, 4, 39
    DOI 10.1186/1476-4598-4-39, PubMed 16274472

Publications 2004

  1. Myklebost O (2004)
    Putting Norway on the gene-therapy map
    Nature, 429 (6988), 129
    DOI 10.1038/429129b, PubMed 15141186

Publications 2002

  1. Meza-Zepeda LA, Forus A, Lygren B, Dahlberg AB, Godager LH, South AP, Marenholz I, Lioumi M, Flørenes VA, Maelandsmo GM, Serra M, Mischke D, Nizetic D, Ragoussis J, Tarkkanen M, Nesland JM, Knuutila S, Myklebost O (2002)
    Positional cloning identifies a novel cyclophilin as a candidate amplified oncogene in 1q21
    Oncogene, 21 (14), 2261-9
    DOI 10.1038/sj.onc.1205339, PubMed 11948409

Publications 2001

  1. Meza-Zepeda LA, Berner JM, Henriksen J, South AP, Pedeutour F, Dahlberg AB, Godager LH, Nizetic D, Forus A, Myklebost O (2001)
    Ectopic sequences from truncated HMGIC in liposarcomas are derived from various amplified chromosomal regions
    Genes Chromosomes Cancer, 31 (3), 264-73
    DOI 10.1002/gcc.1143, PubMed 11391797

Publications 1998

  1. Myklebost O (1998)
    GLI gene and rhabdomyosarcoma
    Nat Med, 4 (8), 869
    DOI 10.1038/nm0898-869c, PubMed 9701218

Publications 1996

  1. Myklebost O (1996)
    First for biotech
    Nature, 384 (6606), 208
    DOI 10.1038/384208b0, PubMed 8918866

Publications 1993

  1. ANDREASSEN A, BORRESEN AL, OYJORD T, SOLHEIM OP, FLORENES VA, BRULAND O, MYKLEBOST O, HOIE J, FODSTAD O (1993)
    CHROMOSOME-17P ABERRATIONS AND P53 EXPRESSION IN HUMAN SARCOMAS
    FRONTIERS OF OSTEOSARCOMA RESEARCH: INTERDISCIPLINARY SURVEY OF CLINICAL AND RESEARCH ADVANCES, 419-422

Publications 1990

  1. Myklebost O, Rogne S, Hjermann I, Olaisen B, Prydz H (1990)
    Association analysis of lipid levels and apolipoprotein restriction fragment length polymorphisms
    Hum Genet, 86 (2), 209-14
    DOI 10.1007/BF00197707, PubMed 1979958

Publications 1986

  1. Myklebost O, Rogne S (1986)
    The gene for human apolipoprotein CI is located 4.3 kilobases away from the apolipoprotein E gene on chromosome 19
    Hum Genet, 73 (4), 286-9
    DOI 10.1007/BF00279087, PubMed 3017837
  2. Rogne S, Myklebost O, Olaisen B, Gedde-Dahl T, Prydz H (1986)
    Confirmation of the close linkage between the loci for human apolipoproteins AI and AIV by the use of a cloned cDNA probe and two restriction site polymorphisms
    Hum Genet, 72 (1), 68-71
    DOI 10.1007/BF00278820, PubMed 3002953

Publications 1985

  1. Rogne S, Rønning OW, Myklebost O, Seglen PO, Pettersen EO (1985)
    Cell cycle traverse and protein metabolism in human NHIK 3025 cells: the role of anchorage
    J Cell Physiol, 125 (3), 528-32
    DOI 10.1002/jcp.1041250324, PubMed 4066771
  2. Shaw DJ, Meredith AL, Sarfarazi M, Huson SM, Brook JD, Myklebost O, Harper PS (1985)
    The apolipoprotein CII gene: subchromosomal localisation and linkage to the myotonic dystrophy locus
    Hum Genet, 70 (3), 271-3
    DOI 10.1007/BF00273455, PubMed 2991117

Publications 1984

  1. Humphries SE, Williams L, Myklebost O, Stalenhoef AF, Demacker PN, Baggio G, Crepaldi G, Galton DJ, Williamson R (1984)
    Familial apolipoprotein CII deficiency: a preliminary analysis of the gene defect in two independent families
    Hum Genet, 67 (2), 151-5
    DOI 10.1007/BF00272990, PubMed 6547689
  2. Myklebost O, Rogne S, Olaisen B, Gedde-Dahl T, Prydz H (1984)
    The locus for apolipoprotein CII is closely linked to the apolipoprotein E locus on chromosome 19 in man
    Hum Genet, 67 (3), 309-12
    DOI 10.1007/BF00291359, PubMed 6088388
  3. Myklebost O, Williamson B, Markham AF, Myklebost SR, Rogers J, Woods DE, Humphries SE (1984)
    The isolation and characterization of cDNA clones for human apolipoprotein CII
    J Biol Chem, 259 (7), 4401-4
    PubMed 6546757

Publications 1983

  1. Humphries SE, Jowett NI, Williams L, Rees A, Vella M, Kessling A, Myklebost O, Lydon A, Seed M, Galton DJ (1983)
    A DNA polymorphism adjacent to the human apolipoprotein CII gene
    Mol Biol Med, 1 (5), 463-71
    PubMed 6094958
 
Page visits: 6301